{
  "image_filename": "figure_p10_det_9_000.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/figure_p10_det_9_000.png",
  "image_type": "Figure",
  "page_number": 10,
  "block_id": "det_9_000",
  "claim_id": "claim_003",
  "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
  "supports_claim": false,
  "explanation": "A flowchart outlining influenza vaccination dose recommendations for children aged 6 months\u20138 years in the 2022\u201323 season based on prior receipt of \u22652 doses of trivalent or quadrivalent vaccine before July 1, 2022, directing either one or two doses of 2022\u201323 vaccine. The figure only presents a dosing algorithm based on vaccination history and does not provide any data or discussion on recombinant vaccine technology, immune response breadth, cross-protection, or mismatch seasons, so it does not support the claim.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A flowchart outlining influenza vaccination dose recommendations for children aged 6 months\u20138 years in the 2022\u201323 season based on prior receipt of \u22652 doses of trivalent or quadrivalent vaccine before July 1, 2022, directing either one or two doses of 2022\u201323 vaccine.",
    "evidence_found": null,
    "reasoning": "The figure only presents a dosing algorithm based on vaccination history and does not provide any data or discussion on recombinant vaccine technology, immune response breadth, cross-protection, or mismatch seasons, so it does not support the claim.",
    "confidence_notes": null
  }
}